Abstract: Embodiments relate to a waveform processing device. The device can include a first input node configured to receive a first signal and a second input node configured to receive a second signal. The device can include a pulse generator including a self-timed digital converter (DTC) with a clock generator (CLK). The device can include a switching network configured to be driven by an output from the pulse generator to modulate the first signal and the second signal in synchronization.

Abstract: The present application relates to a nucleic acid molecule comprising a promoter operably linked to a nucleic acid sequence encoding Myocyte Enhancer Factor 2C (MEF2C), or a functional variant thereof, wherein the promoter is for expression of MEF2C in macroglia. Also provided are vectors, compositions, products, methods, cells, medical uses and methods of treatment.

Abstract: The present invention relates to humanised antibodies that bind amyloid peptides, which antibodies comprise mutations in the heavy chain and/or light chain variable domains, which mutations improve the binding activity. The antibodies may be useful in the treatment of Alzheimer's disease (AD).

Abstract: This invention relates to humanised versions of the murine anti-IL17BR antibody D9.2 which comprise mutations of certain residues within the heavy chain and/or light chain variable domains that display improved expression without deleterious effects on specificity or affinity. The humanised antibodies may comprise a heavy chain variable (VH) domain which comprises a VHCDR1 of SEQ ID NO: 1, a VHCDR2 of SEQ ID NO: 2, and a VHCDR3 of SEQ ID NO: 3, for example, a VH domain of SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11. The humanised antibodies may comprise a light chain variable (VL) domain which comprises a VLCDR1 of SEQ ID NO: 4, a VLCDR2 of SEQ ID NO: 5, and a VLCDR3 of SEQ ID NO: 6, for example a VL domain of SEQ ID NO: 13. Antibodies, pharmaceutical compositions and methods of use, for example in the treatment of cancer are provided.

Abstract: A reclosable enclosure includes front and back panels and a reclosable mechanism. The front panel and the back panel are coupled to each other and form an interior cavity therebetween. The front panel is configured to form an access slot that extends widthwise along the front panel. The reclosable mechanism is coupled to an interior side of the front panel along the access slot. The reclosable mechanism has a first profile and a second profile forming a zipper. The first profile includes a user tab that is accessible through the access slot. The user tab is configured to assist in separating the first and second profiles to provide an opening to the interior cavity of the reclosable enclosure.

Abstract: A resealable bag enclosure may be provided that includes a film having an opposing first side and second side coupled with each other, and a resealable zipper assembly coupled with the first side and the second side of the film. The first side and the second side of the film together may form a pattern at an opening stop location disposed between the first and second edges of the film and adjacent to an end of the zipper assembly. The pattern of the first side and the second side of the film may also resist opening of the resealable bag enclosure beyond the end of the zipper assembly when the first side and the second side of the film are pulled apart to prevent the peel seal from extending beyond the pattern.

Abstract: The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.

Abstract: The present invention relates to humanised antibodies that bind amyloid peptides, which antibodies comprise mutations in the heavy chain and/or light chain variable domains, which mutations improve the binding activity. The antibodies may be useful in the treatment of Alzheimer's disease (AD).

Abstract: The present invention relates to cyclized peptides based on amino acids 1-14 of amyloid-beta. The cyclic peptides are useful for inducing an immune response and as vaccines for the treatment of neurodegenerative diseases such as Alzheimer's disease.

Abstract: The method and apparatus relate to reclosures in a transverse direction (TD) application, wherein the reclosures include only one consumer side flange, rather than two. That is, the reclosures are missing a flange on the consumer side. A first aspect of the disclosure fills the inverted pouch or package and orients the reclosure with the consumer flange on the leading edge. A second aspect of the disclosure fills the package in a non-inverted configuration and includes a peel seal between the two product side leading flanges below the profile.

Abstract: This invention relates to humanised versions of the murine anti-IL17BR antibody D9.2 which comprise mutations of certain residues within the heavy chain and/or light chain variable domains that display improved expression without deleterious effects on specificity or affinity. The humanised antibodies may comprise a heavy chain variable (VH) domain which comprises a VHCDR1 of SEQ ID NO: 1, a VHCDR2 of SEQ ID NO: 2, and a VHCDR3 of SEQ ID NO: 3, for example, a VH domain of SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11. The humanised antibodies may comprise a light chain variable (VL) domain which comprises a VLCDR1 of SEQ ID NO: 4, a VLCDR2 of SEQ ID NO: 5, and a VLCDR3 of SEQ ID NO: 6, for example a VL domain of SEQ ID NO: 13. Antibodies, pharmaceutical compositions and methods of use, for example in the treatment of cancer are provided.

Abstract: A resealable bag enclosure may be provided that includes a film having an opposing first side and second side coupled with each other, and a resealable zipper assembly coupled with the first side and the second side of the film. The first side and the second side of the film together may form a pattern at an opening stop location disposed between the first and second edges of the film and adjacent to an end of the zipper assembly. The pattern of the first side and the second side of the film may also resist opening of the resealable bag enclosure beyond the end of the zipper assembly when the first side and the second side of the film are pulled apart to prevent the peel seal from extending beyond the pattern.

Abstract: The present invention relates to humanised antibodies that bind amyloid peptides, which antibodies comprise mutations in the heavy chain and/or light chain variable domains, which mutations improve the binding activity. The antibodies may be useful in the treatment of Alzheimer's disease (AD).

Abstract: The present disclosure relates to resealable zippers or reclosures for flexible packaging which is child-deterrent or child-resistant. This zipper or reclosure includes two profiles, wherein at least one profile includes a tab created from flange material between upper and lower sets of interlocking elements. The user grasps the tab to separate the two profiles in order to open the packaging. The flange may alternatively include a finger aperture or a finger slit.

Abstract: The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.

Abstract: The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.

Abstract: The present disclosure relates to a reclosures in a transverse direction (TD) application, wherein the reclosures include only one consumer side flange, rather than two. That is, the reclosures are missing a flange on the consumer side. A first aspect of the disclosure fills the inverted pouch or package and orients the reclosure with the consumer flange on the leading edge. A second aspect of the disclosure fills the package in a non-inverted configuration and includes a peel seal between the two product side leading flanges below the profile.

Abstract: The example embodiments are directed to a system and method for simulating an application performance using a test environment associated with an application marketplace where the application can be purchased. In one example, the method may include operating a virtual test environment which includes virtual hardware for testing software, receiving, from the application marketplace, information about an application and operating characteristics of a target installation environment for the application, executing the application via the virtual hardware of the virtual test environment based on the operating characteristics of the target installation environment to generate simulated test results of the application in the target installation environment, and outputting information of the simulated application test results for the target installation environment for display on a display device.

Abstract: The example embodiments are directed to a system and method for incorporating licensing information into a downloadable application via an application marketplace. In an example, the method includes one or more of receiving a request of an asset control system, at an application marketplace, to download and install an instance of a software application from the application marketplace for use with an asset controlled by the asset control system, dynamically determining a licensing scheme to be used for the instance of the software application from among a plurality of possible licensing schemes based on configuration information stored in a repository associated with the application marketplace, assigning the dynamically determined licensing scheme to a downloadable file of the software application, and transmitting the downloadable file having the dynamically assigned licensing scheme to an industrial edge computing system associated with the asset control system.

Abstract: The example embodiments are directed to a system and method for determining an improvement to an asset created by installation of a software application associated with the asset. In one example, the method includes determining an operating performance of an asset operating based on a performance modifying application being installed, establishing a baseline operating performance of the asset from a virtual model of the asset which is running without the performance modifying application installed, determining a change in an operating characteristic of the asset in response to the performance modifying application being installed based on the operating performance of the asset determined from the asset and the baseline operating performance of the asset determined from the virtual model of the asset, and outputting information about the determined change in the operating characteristic of the asset for display on a display device.